Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CSL ( (AU:CSL) ) is now available.
CSL Limited announced the cessation of 9,078 securities due to the lapse of conditional rights as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders regarding the company’s operational strategies and market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$300.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and distribution of innovative biopharmaceutical products. The company is known for its work in producing medicines that treat serious human illnesses, including those related to immunology and hematology.
Average Trading Volume: 1,183,721
Technical Sentiment Signal: Sell
Current Market Cap: A$100.8B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.